https://www.sagemedic.com/post/understanding-how-functional-testing-may-help-inform-cancer-treatment-discussions 2026-07-03 https://www.sagemedic.com/post/sage-oncotest-reveal-identifies-marked-ovarian-cancer-drug-response-heterogeneity-and-potential-alt 2026-07-03 https://static.wixstatic.com/media/436c32_a279c10814af4dfba159f15e5cb02e35~mv2.jpg Patient-derived ovarian cancer tissue can be evaluated as viable 3D microtumors for ex vivo treatment-response assessment. This visual connects the clinical specimen, preserved tumor architecture, and heterogeneous dose-response patterns to carboplatin, paclitaxel, and carboplatin/paclitaxel.